Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia

This Phase 3 study in adult participants with newly diagnosed low-risk APL will evaluate the efficacy, safety, and PK of an oral capsule formulation of ATO, in combination with ATRA.

Trial Details

NCT ID
NCT07504458
Phase
PHASE3
Sponsor
Quetzal Therapeutics
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • QTX-2101 + ATRA
  • IV arsenic trioxide (ATO) + ATRA
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Los Angeles, California, United States|34.05223,-118.24368
  • Orange, California, United States|33.78779,-117.85311

Key Eligibility Criteria

  • Informed Consent
  • Participants must be between 18 and under 71 years of age
  • Participants must have a confirmed diagnosis of APL proven by standard genetic testing (t(15;17) or PML-RARA)
  • Participants must be classified as low- or intermediate-risk APL

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →